McKesson raised fiscal 2026 EPS guidance as oncology, distribution, technology services, and cash generation remained strong.
| Quarter | Q3 FY26 |
|---|---|
| Call date | 2026-02-05 |
| Length | 59 minutes |
| EPS | $9.34 |
| EPS consensus | $9.31 |
| Revenue | $106.2B |
What changed, guidance prior to now, analyst Q&A candor and the case for and against are part of Core.
Other quarters: Q1 FY26
All MCK earnings ยท Back to MCK overview
Transcript produced by Signals.AI from the company's own earnings call audio. Not personalized investment advice.